The filing confirms strong operating momentum with record shipments and expanding profitability. Monitor next 20-F for sustained revenue growth above 30% and continued improvement in adjusted EBITDA guided at $13-14M for FY2026. The accelerated adoption of Deep TMS and SWIFT protocol supports a positive medium-term outlook.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 13 $16.47entry
- T+1 · 3mo ago −0.91%α −0.71% · $16.32
- T+5 · 3mo ago −9.11%α −7.14% · $14.97
- T+20 · 2mo ago −15.42%α −13.67% · $13.93
- T+60 · 11d ago −32.30%α −26.83% · $11.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Brainsway Ltd. furnished an August 2026 investor deck via Form 6-K, presenting strong H1 2026 financial results: revenue grew +35% year-over-year, net income +34%, adjusted EBITDA +141%, and system shipments rose +42% to 125 units. The filing reiterates the company's strategic positioning as a Deep TMS platform leader with 4 FDA indications, expanding reimbursement, and a capital-light clinic network model. The deck is forward-looking and promotional in nature, reinforcing the growth narrative established in the prior 20-F annual report.
Key Facts
- Q2 2026 system shipments of 125 units, up +42% year-over-year.
- Revenue growth of +35%, net income +34%, adjusted EBITDA +141%.
- Gross margin reported at 75%.
- Remaining Performance Obligations (RPO) grew +$80 million (+30% year-over-year).
- Operating income increased +314%, cash balance at $62.4 million.
- 90%+ customer retention rate and 1.3x book-to-bill ratio.
- More than 1,950 systems installed across 48 states and 6 continents.
- Valor Equity Partners (largest investor) backs strategic clinic network expansion.
- Home therapy enabled via $11M convertible investment in Neurolief with call option.
- Filed on Form 6-K under cover of the 1934 Act, incorporated by reference into existing F-3 and S-8 registration statements.
Financial Impact
Revenue $52.2M in FY2025; H1 2026 revenue +35% YoY; Adj. EBITDA +141%; net income +34%; cash $62.4M
Risk Factors
- Reliance on single large customer as noted in prior annual filing.
- Patent litigation with Magnus Medical remains a potential overhang.
- Forward-looking statements are promotional and not guaranteed; reimbursement changes could slow adoption.
- International expansion carries execution risk across multiple regulatory jurisdictions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005454 |
| Document: f6k_081226.htm | 0001171843-26-005454 |
| Document: 0001171843-26-005454-index-headers.html | 0001171843-26-005454 |
| Document: 0001171843-26-005454-index.html | 0001171843-26-005454 |
| Document: 0001171843-26-005454.txt | 0001171843-26-005454 |
Track record
24 reports on BWAY
6 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +27.55% at T+60 after the Mar 4, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Bullish 6/10 No price data
- Nov 10, 20266d ago 6-K Neutral 5/10 Entry $10.67 Now $9.39 −12.00% settles Dec 9
- Nov 2, 202614d ago 6-K Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Oct 26, 202621d ago 6-K Neutral 3/10 Entry $11.21 Now $9.39 −16.24% settles Nov 23
- Oct 21, 202626d ago 6-K Neutral 3/10 Entry $11.44 Now $9.39 −17.92% settles Nov 19
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $11.99 to $9.39 Now $9.39 −21.68% ▼ −21.68% −18.22% vs SPY
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $11.99 to $9.39 Now $9.39 −21.68% ▼ −21.68% −18.22% vs SPY
- Oct 13, 20264w ago 6-K Neutral 4/10 Entry $11.92 to $10.67 Now $9.39 −21.22% ▼ −10.49% −6.88% vs SPY
- Sep 8, 20269w ago 6-K Neutral 4/10 Entry $14.16 to $11.89 Now $9.39 −33.69% ▼ −16.03% −18.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers